1. Home
  2. QNC vs ASMB Comparison

QNC vs ASMB Comparison

Compare QNC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$1.96

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$35.19

Market Cap

512.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
ASMB
Founded
2007
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
512.1M
IPO Year
2026
2010

Fundamental Metrics

Financial Performance
Metric
QNC
ASMB
Price
$1.96
$35.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$44.20
AVG Volume (30 Days)
415.4K
269.5K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$638.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$20.23
52 Week High
$3.59
$39.71

Technical Indicators

Market Signals
Indicator
QNC
ASMB
Relative Strength Index (RSI) 31.99 66.82
Support Level N/A $25.86
Resistance Level $2.60 $38.63
Average True Range (ATR) 0.10 2.10
MACD -0.01 0.15
Stochastic Oscillator 3.97 82.21

Price Performance

Historical Comparison
QNC
ASMB

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: